Professor Daniel Galvão is a leading academic in exercise oncology at Edith Cowan University (ECU), Australia. He serves as Director of the Exercise Medicine Research Institute and holds a Professorship in Exercise and Sports Science within the School of Medical and Health Sciences. His research focuses on optimizing exercise interventions to mitigate treatment-related toxicities and improve outcomes for cancer patients, particularly those with prostate cancer. Galvão has secured over $26 million in grants from bodies like the NHMRC, Movember Foundation, and Cancer Australia, supporting multidisciplinary trials and survivorship programs. Education: PhD (Edith Cowan University, 2006), Master of Applied Science in Clinical Exercise Science (University of Queensland, 2003). His career includes roles as Co-Director of ECU’s Health and Wellness Institute and Fellowships with the American College of Sports Medicine and Exercise and Sports Science Australia. Research emphasizes exercise as medicine in oncology, with over 200 peer-reviewed publications. Key contributions include guidelines for exercise in cancer patients and landmark trials like ERADICATE (prostate cancer radiotherapy adjuncts) and TelEX (weight management for prostate cancer). Notable awards include the 2021 Asian Pacific Prostate Cancer Conference Best Poster, 2014 Edith Cowan Vice-Chancellor’s Award, and 2007 ESSA PhD Medal. He chairs national research committees and reviews for high-impact journals like Journal of Clinical Oncology and European Urology . Current initiatives include nationwide exercise programs for prostate cancer survivors and translational research on myokine mechanisms in cancer suppression. His work bridges clinical practice with evidence-based interventions to enhance patient quality of life and survival outcomes.




